OpGen, Inc. (OPGN): Price and Financial Metrics

OpGen, Inc. (OPGN): $2.25

0.05 (+2.27%)

POWR Rating

Component Grades














  • OPGN scores best on the Sentiment dimension, with a Sentiment rank ahead of 56.83% of US stocks.
  • OPGN's strongest trending metric is Sentiment; it's been moving up over the last 31 weeks.
  • OPGN's current lowest rank is in the Stability metric (where it is better than 2.65% of US stocks).

OPGN Stock Summary

  • With a price/sales ratio of 19.02, Opgen Inc has a higher such ratio than 89.73% of stocks in our set.
  • With a year-over-year growth in debt of 810.83%, Opgen Inc's debt growth rate surpasses 98.17% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for OPGN comes in at -63.11% -- higher than that of merely 4.22% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Opgen Inc, a group of peers worth examining would be VJET, IVA, MUX, ANY, and LNDC.
  • OPGN's SEC filings can be seen here. And to visit Opgen Inc's official web site, go to www.opgen.com.

OPGN Valuation Summary

  • OPGN's price/earnings ratio is -2.3; this is 106.76% lower than that of the median Healthcare stock.
  • OPGN's price/sales ratio has moved up 6.7 over the prior 76 months.
  • Over the past 76 months, OPGN's price/sales ratio has gone up 6.7.

Below are key valuation metrics over time for OPGN.

Stock Date P/S P/B P/E EV/EBIT
OPGN 2021-02-11 15.9 3.4 -2.7 -3.6
OPGN 2020-12-16 9.5 2.1 -1.6 -2.4
OPGN 2019-09-03 1.7 3.2 -0.4 -0.5
OPGN 2017-03-09 5.2 6.8 -1.2 -1.0
OPGN 2016-08-23 8.2 4.7 -1.9 -1.6
OPGN 2016-07-19 5.3 6.1 -1.0 -1.0

OPGN Price Target

For more insight on analysts targets of OPGN, see our OPGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.50 Average Broker Recommendation 1.5 (Moderate Buy)

OPGN Stock Price Chart Interactive Chart >

Price chart for OPGN

OPGN Price/Volume Stats

Current price $2.25 52-week high $4.44
Prev. close $2.20 52-week low $1.63
Day low $2.18 Volume 203,300
Day high $2.25 Avg. volume 5,559,935
50-day MA $2.22 Dividend yield N/A
200-day MA $2.29 Market Cap 86.10M

OPGN Latest News Stream

Event/Time News Detail
Loading, please wait...

OPGN Latest Social Stream

Loading social stream, please wait...

View Full OPGN Social Stream

Latest OPGN News From Around the Web

Below are the latest news stories about Opgen Inc that investors may wish to consider to help them evaluate OPGN as an investment opportunity.

OpGen Announces Partial Adjournment of Annual Meeting

Adjournment solely with respect to Proposal 2 (increase in authorized shares)Company and Board to Explore Alternative Options ROCKVILLE, Md., July 07, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that the Company resumed its partially adjourned 2021 annual stockholders meeting (the “Annual Meeting”) on July 7, 2021, solely

Yahoo | July 7, 2021

OpGen Announces Prospective Clinical Data from Unyvero LRT BAL and Acuitas AMR Gene Panel for Isolates Data Presented at World Microbe Forum

- Unyvero studies demonstrated potential for therapy adjustment in 42% to 53% of patients with results available 1 to 2 days faster - Acuitas AMR Gene Panel for Isolates (RUO) studies demonstrate potential in infection control and prevention GAITHERSBURG, Md., June 30, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced prospective clinical da

Yahoo | June 30, 2021

OpGen Group Company Ares Genetics Presents R&D Pipeline Updates

Preliminary data demonstrates robust performance on nanopore sequencingAccuracy of 100% for pathogen identification and up to 97% for AMR markers and up to 100% on predicting AST ROCKVILLE, Md., June 28, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that its subsidiary Ares Genetics, which strives to become a leader in bacterial genomics an

Yahoo | June 28, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Welcome back, traders, and good morning!

William White on InvestorPlace | June 15, 2021

Is OpGen, Inc. (OPGN) A Good Stock To Buy Now?

In this article we will check out the progression of hedge fund sentiment towards OpGen, Inc. (NASDAQ:OPGN) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […]

Yahoo | June 15, 2021

Read More 'OPGN' Stories Here

OPGN Price Returns

1-mo -4.66%
3-mo -2.17%
6-mo 3.69%
1-year 4.17%
3-year -94.05%
5-year -99.81%
YTD 10.29%
2020 80.53%
2019 -95.65%
2018 -72.19%
2017 -83.74%
2016 -39.47%

Continue Researching OPGN

Want to see what other sources are saying about Opgen Inc's financials and stock price? Try the links below:

Opgen Inc (OPGN) Stock Price | Nasdaq
Opgen Inc (OPGN) Stock Quote, History and News - Yahoo Finance
Opgen Inc (OPGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8749 seconds.